Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Novartis

Status and phase: Completed; Phase 2

Conditions: Diabetic Nephropathy

Treatments: Drug: aliskiren

Study type: Interventional

Funder types: Industry

Identifiers

NCT00097955

CSPP100C2201

Details and patient eligibility

About

Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension
• Elevated urinary protein levels
• Confirmed type 2 diabetes

Exclusion criteria

• Certain diseases
• Uncontrolled diabetes
• Type 1 diabetes

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind